Why the study?
Inflammation is a key factor of myocardial damage in reperfused STEMI, leading to the hypothesis that colchicine may reduce infarct size and left ventricular remodeling at the acute phase.
Does oral colchicine reduce infarct size in patients with a first episode of ST-segment-elevation myocardial infarction referred for primary percutaneous coronary intervention?
Does oral colchicine reduce infarct size in patients with a first episode of ST-segment-elevation myocardial infarction referred for primary percutaneous coronary intervention?
High-dose oral colchicine administered at the time of reperfusion and for 5 days does not reduce infarct size in patients with first-time STEMI undergoing primary PCI.
No takes yet. Share an insight, caveat, or question.
Colchicine does not reduce infarct size in first STEMI; challenges adjunctive anti-inflammatory therapy at primary PCI.
Mewton et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: